| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Silvia Colucci | Q37829968 |
| Graziana Colaianni | Q40380187 | ||
| P2093 | author name string | Concetta Cuscito | |
| P2860 | cites work | Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships | Q28210588 |
| Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone | Q28511219 | ||
| FSH directly regulates bone mass | Q28512745 | ||
| Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice | Q28590055 | ||
| What Is the Missing Hormonal Factor Controlling Menopausal Bone Resorption? | Q82315565 | ||
| FSH versus estrogen: who's guilty of breaking bones? | Q83297326 | ||
| FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women | Q83900950 | ||
| Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density | Q84854205 | ||
| The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. | Q46655003 | ||
| Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma | Q46869239 | ||
| Effects of recombinant follicle-stimulating hormone on bone turnover markers in infertile women undergoing in vitro fertilization procedure. | Q46906948 | ||
| Risk for fracture in women with low serum levels of thyroid-stimulating hormone | Q46921467 | ||
| Bone loss goes beyond estrogen | Q48505837 | ||
| Thyroid hormone and bone mass: the clinician's dilemma. | Q51137982 | ||
| Transmenopausal changes in the trabecular bone structure. | Q53481955 | ||
| Perimenopause: The Complex Endocrinology of the Menopausal Transition | Q56083839 | ||
| The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice | Q73382472 | ||
| TSH Is a Negative Regulator of Skeletal Remodeling | Q79184844 | ||
| Aromatase expression in osteoarthritic and osteoporotic bone | Q81361016 | ||
| Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation | Q31717820 | ||
| Follicle-stimulating hormone, interleukin-1, and bone density in adult women | Q33728125 | ||
| Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo | Q33950241 | ||
| Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. | Q34262504 | ||
| Follicle-stimulating hormone increases bone mass in female mice | Q34450203 | ||
| Follicle-stimulating hormone promotes RANK expression on human monocytes | Q34494324 | ||
| Estrogen deficiency and bone loss: an inflammatory tale | Q34576622 | ||
| The TSH receptor reveals itself. | Q34744982 | ||
| TNFalpha mediates the skeletal effects of thyroid-stimulating hormone | Q35036487 | ||
| Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation | Q35075554 | ||
| Growth hormone regulates the balance between bone formation and bone marrow adiposity | Q35156064 | ||
| Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression | Q35169193 | ||
| Quantification of the roles of trabecular microarchitecture and trabecular type in determining the elastic modulus of human trabecular bone | Q35575608 | ||
| Follicle-stimulating hormone is independently associated with lean mass but not BMD in younger postmenopausal women | Q35635694 | ||
| Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. | Q36217229 | ||
| Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis | Q36221704 | ||
| TSH and bone loss | Q36532548 | ||
| High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence | Q36629269 | ||
| Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss | Q36670143 | ||
| Guidelines for the diagnosis of osteoporosis: T-scores vs fractures | Q36691243 | ||
| Follicle stimulating hormone and its rate of change in defining menopause transition stages | Q36964899 | ||
| Oxytocin is an anabolic bone hormone | Q37182727 | ||
| Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha | Q37271202 | ||
| Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone | Q37361535 | ||
| Follicle-stimulating hormone does not impact male bone mass in vivo or human male osteoclasts in vitro | Q38291172 | ||
| Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio | Q40029157 | ||
| Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats | Q40160316 | ||
| Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. | Q42526719 | ||
| The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. | Q44309056 | ||
| Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. | Q45300463 | ||
| Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects | Q46102174 | ||
| Hormone predictors of bone mineral density changes during the menopausal transition | Q46161694 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immune system | Q1059 |
| nervous system | Q9404 | ||
| endocrine system | Q11078 | ||
| hormone | Q11364 | ||
| osteoporosis | Q165328 | ||
| peptide | Q172847 | ||
| tissue | Q40397 | ||
| regulation of gene expression | Q411391 | ||
| human musculoskeletal system | Q726543 | ||
| hemic and immune systems | Q70202933 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 382698 | |
| P577 | publication date | 2013-05-30 | |
| P1433 | published in | Clinical and Developmental Immunology | Q15754140 |
| P1476 | title | FSH and TSH in the regulation of bone mass: the pituitary/immune/bone axis | |
| P478 | volume | 2013 |
| Q26747476 | Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies |
| Q37395073 | Bone Mineral Density in Adolescent Girls with Hypogonadotropic and Hypergonadotropic Hypogonadism |
| Q37054103 | Bone Mineral Status in Children and Adolescents with Klinefelter Syndrome |
| Q36295335 | Bone mineral density is associated with vitamin D related rs6013897 and estrogen receptor polymorphism rs4870044: The Tromsø study. |
| Q54205974 | Brain to bone: What is the contribution of the brain to skeletal homeostasis? |
| Q35035478 | Conditional disruption of miR17-92 cluster in collagen type I-producing osteoblasts results in reduced periosteal bone formation and bone anabolic response to exercise |
| Q64075023 | FSH Beyond Fertility |
| Q36716103 | FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year After Treatment |
| Q48135442 | Follicle-Stimulating Hormone β-Subunit Potentiates Bone Morphogenetic Protein 9-Induced Osteogenic Differentiation in Mouse Embryonic Fibroblasts. |
| Q55365511 | In Vivo and In Vitro Impact of Carbohydrate Variation on Human Follicle-Stimulating Hormone Function. |
| Q55714856 | MC3T3 infiltration and proliferation in bovine trabecular scaffold regulated by dynamic flow bioreactor and augmented by low-intensity pulsed ultrasound. |
| Q34356431 | Oxytocin and bone |
| Q98289688 | Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer |
| Q37145950 | Severity and pattern of bone mineral loss in endocrine causes of osteoporosis as compared to age-related bone mineral loss |
| Q36686413 | The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice |
| Q48012365 | The associations of bedtime, nocturnal, and daytime sleep duration with bone mineral density in pre- and post-menopausal women |
Search more.